cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Company profile
Ticker
CERS
Exchange
Website
CEO
William Greenman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cerus Europe ...
IRS number
680262011
CERS stock data
Latest filings (excl ownership)
8-K
Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors
2 Jul 24
8-K
Departure of Directors or Certain Officers
11 Jun 24
SD
Conflict minerals disclosure
31 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Cerus Corporation Announces First Quarter 2024 Financial Results
2 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
8-K
Other Events
19 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
Transcripts
CERS
Earnings call transcript
2024 Q1
2 May 24
CERS
Earnings call transcript
2023 Q4
5 Mar 24
CERS
Earnings call transcript
2023 Q3
2 Nov 23
CERS
Earnings call transcript
2023 Q2
2 Aug 23
CERS
Earnings call transcript
2023 Q2
2 Aug 23
CERS
Earnings call transcript
2023 Q1
4 May 23
CERS
Earnings call transcript
2022 Q4
28 Feb 23
CERS
Earnings call transcript
2022 Q3
3 Nov 22
CERS
Earnings call transcript
2022 Q2
4 Aug 22
CERS
Earnings call transcript
2022 Q1
6 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 22.24 mm | 22.24 mm | 22.24 mm | 22.24 mm | 22.24 mm | 22.24 mm |
Cash burn (monthly) | (no burn) | 596.17 k | 3.21 mm | 2.61 mm | (no burn) | 2.73 mm |
Cash used (since last report) | n/a | 2.31 mm | 12.39 mm | 10.11 mm | n/a | 10.54 mm |
Cash remaining | n/a | 19.93 mm | 9.84 mm | 12.12 mm | n/a | 11.69 mm |
Runway (months of cash) | n/a | 33.4 | 3.1 | 4.6 | n/a | 4.3 |
Institutional ownership, Q1 2024
71.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 135 |
Opened positions | 127 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 243.50 bn |
Total shares | 131.81 mm |
Total puts | 60.90 k |
Total calls | 39.60 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 21.55 mm | $40.72 bn |
Baker Bros. Advisors | 19.48 mm | $36.81 bn |
BLK Blackrock | 13.64 mm | $25.77 bn |
Vanguard | 9.98 mm | $18.87 bn |
CMTDF Sumitomo Mitsui Trust | 7.75 mm | $14.65 bn |
Nikko Asset Management Americas | 7.75 mm | $14.57 bn |
Senvest Management | 7.33 mm | $13.85 bn |
Wasatch Advisors | 6.28 mm | $11.88 bn |
Geode Capital Management | 4.16 mm | $7.87 bn |
STT State Street | 3.67 mm | $6.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | Dean A. Gregory | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 60,000 |
5 Jun 24 | Eric Bjerkholt | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 182,133 |
5 Jun 24 | Ann Lucena | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 112,284 |
5 Jun 24 | Moore Timothy L. | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 145,073 |
News
ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
17 Jul 24
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
17 Jul 24
Zomedica And 3 Other Stocks Under $3 Insiders Are Buying
14 May 24
ESS Tech And 2 Other Stocks Under $5 Insiders Are Buying
10 May 24
Cantor Fitzgerald Maintains Overweight on Cerus, Raises Price Target to $4
3 May 24
Press releases
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
18 Jul 24
Cerus Corporation Celebrates World Blood Donor Day 2024
14 Jun 24
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
22 May 24
Cerus Corporation Announces First Quarter 2024 Financial Results
2 May 24